Hopp til hovedinnhold

Testikkelkreft

Sist oppdatert: Sist revidert:
Sist revidert av:
Definisjon:
Ukontrollert cellevekst som utgår fra germinalvevet utgjør 90-95% av alle tilfeller, utgjøres av to hovedtyper. Kryptorkisme øker risikoen
Forekomst:
Ca. 300 nye tilfeller årlig, og 98% er fortsatt i live 5 år etter diagnosen. Norge og Danmark har den høyeste insidens i verden. Den hyppigste kreftform blant yngre menn
Symptomer:
Som oftest er testikkelen uøm, men tyngdefornemmelse er vanlig. 10-20% har smerter
Funn:
Ved palpasjon kjennes svulsten hyppigst ventralt eller lateralt i en diffust forstørret testis, men den angrepne testikkelen kan også være mindre enn normalt
Diagnostikk:
Tidlig utredning skjer gjennom tumormarkører og ultralyd
Behandling:
Kirurgi, cytostatika og stråler er aktuelle behandlingsformer. Behandlingen gir helbredelse hos mer enn 95%
  1. Baird DC, Meyers GJ, Hu JS. Testicular Cancer: Diagnosis and Treatment. Am Fam Physician. 2018;97(4):261-268. PubMed  
  2. Sobin LH, Witterkind C: TNM classification of malignant tumours., UICC Wiley-Liss, 2007.
  3. International Germ Cell Consensus Classification: a prognostic factor- based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603. PubMed  
  4. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av testikkelkreft. Sist faglig oppdatert: 15. april 2021. www.helsebiblioteket.no  
  5. Kreftregisteret. Cancer in Norway 2019. Oslo: Kreftregisteret, 2020. www.kreftregisteret.no.
  6. Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, McGlynn KA. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev. 2010 May. 19(5):1151-9.
  7. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G et al. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 2005; 16: 863-8. PubMed  
  8. Lip SZ, Murchison LE, Cullis PS, Govan L, Carachi R. A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. Arch Dis Child. 2013;98(1):20–26. PMID: 23193201 PubMed  
  9. Jacobsen R, Bostofte E, Engholm G, Hansen J, Olsen JH, Skakkebaek NE, et al. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. . BMJ 2000; 321: 789-92. PubMed  
  10. Hemminki K, Chen B. Familial risks in testicular cancer as aetiological clues. Int J Androl 2006; 29:205. PubMed  
  11. Levin HS. Tumors of the testis in intersex syndromes. Urol Clin North Am 2000; 27: 543-51. PubMed  
  12. Shephard EA, Hamilton WT. Selection of men for investigation of possible testicular cancer in primary care: a large case-control study using electronic patient records. Br J Gen Pract 2018. pmid:29970393 PubMed  
  13. Oldenburg J, Lehne G, Fosså S. Testikkelkreft. Tidsskr Nor Legeforen 2008; 128: 457-60. PubMed  
  14. Albers P, Albrecht W, Algaba F, et al.; European Association of Urology. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68(6):1054–1068. PMID: 26297604 PubMed  
  15. Coursey Moreno C, Small WC, Camacho JC, et al. Testicular tumors: what radiologists need to know—differential diagnosis, staging, and management. Radiographics. 2015;35(2):400–415.
  16. Steele GS, Richie JP, Oh WK, Michaelson MD. Clinical manifestations, diagnosis, and staging of testicular germ cell tumors. UpToDate, last updated Jan 25, 2021. UpToDate  
  17. Venkitaraman R, Johnson B, Huddart RA et al. The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours. BJU Int 2007; 100: 30-2. PubMed  
  18. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EHCCCG): Part I. European Urology 2008; 53: 478-96. PubMed  
  19. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EHCCCG): Part II. European Urology 2008; 53: 497-513. PubMed  
  20. Einhorn LH, Williams SD, Chamness A et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357: 340-8. New England Journal of Medicine  
  21. Brydoy M, Oldenburg J, Klepp O et al. Self-reported paresthesias, Raynaud’s phenomena, tinnitus, and hearing impairment in a large cohort of long-term testicular cancer (TC) survivors. J Clin Oncol (Meeting Abstracts) 2006; 24: 4547. PubMed  
  22. Choo R, Thomas G, Woo T et al. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2005; 61: 736-40. PubMed  
  23. Warde P, Chung P, Sturgeon J et al. Should surveillance be considered the standard of care in stage I seminoma?. J Clin Oncol 2005; 23 (suppl 16): 4520.
  24. Oliver RTD, Mason MD, van der Maase H et al. Radiotherapy versus single dose carboplatin in adjuvant treatment of stage I testicular seminoma: a randomised trial. Lancet 2005; 366: 293-300. PubMed  
  25. Warde P, Gospodarowicz M. Adjuvant carbopaltin in stage I seminoma. Lancet 2005; 366: 267-8. PubMed  
  26. Rosendal S, Kristensen E, Giraldi AGE. Seksuelle dysfunktioner hos mænd, der er behandlet for testikelkræft. Ugeskr Læger 2007; 169: 3941. PubMed  
  27. Fung C, Fossa SD, Williams A, Travis LB. Long-term morbidity of testicular cancer treatment. Urol Clin North Am 2015; 42: 393-408. PMID: 26216826 PubMed  
  • Terje Johannessen, professor i allmennmedisin, Trondheim

Tidligere fagmedarbeidere

  • Truls E. Bjerklund Johansen, prof. dr. med., Urologisk afdeling, Århus Universitetshospital, 8200 Århus, DK
  • Jan Oldenburg, dr. med., forsker, Radiumhospitalet, Oslo
  • Svein Z. Bratland, spesialist i allmennmedisin, Sandviken Legesenter, Bergen, og seniorrådgiver i Statens helsetilsyn, Oslo